Background: Retardation and agitation are symptoms of major depressive disorder (MDD), and their presence could play a role in determining clinically meaningful depressive subtypes such as nonmelancholic depression (NMD) and melancholic depression (MD). In this project, we explored whether three depression subgroups (NMD, MD with psychotic symptoms, and MD without psychotic symptoms) could be distinguished based on objective measures of psychomotor functioning. Methods: Sixty-nine patients with MDD underwent extensive clinical and psychomotor testing prior to treatment with electroconvulsive therapy. Psychomotor functioning was assessed subjectively using the Core Assessment of Psychomotor Change (CORE) and objectively by means of both 24-h actigraphy and performance on a fine motor drawing task. Results: The daytime activity levels measured by actigraphy were significantly lower (F = 7.1, p = 0.0004) in MD patients both with and without psychotic symptoms than in those with NMD. No objective psychomotor variable was able to distinguish between melancholic patients with and those without psychotic symptoms. Conclusions: The depression subtypes NMD, MD with psychotic symptoms, and MD without psychotic symptoms are not marked by increasing psychomotor retardation, possibly because psychomotor disturbance in MD with psychotic symptoms often consists of agitation rather than retardation, or a mixture of the two. However, psychomotor functioning as measured by actigraphy can be used to distinguish between NMD patients and MD patients.

Keywords:
Psychomotor functioning, Major depressive disorder, Retardation, Agitation
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 5. Arlington, American Psychiatric Association, 2013.
2.
Parker G: Classifying depression: should paradigms lost be regained? Am J Psychiatry 2000; 157: 1195–1203.
3.
Parker G, Hadzi-Pavlovic D: Melancholia: A Disorder of Movement and Mood – A Phenomenological and Neurobiological Review. Cambridge, Cambridge University Press, 1996.
4.
Caldieraro MAK, Baeza FLC, Pinheiro DO, Ribeiro MR, Parker G, Fleck MP: Clinical differences between melancholic and nonmelancholic depression as defined by the CORE system. Compr Psychiatry 2013; 54: 11–15.
5.
Parker G, McCraw S: The properties and utility of the CORE measure of melancholia. J Affect Disord 2017; 207: 128–135.
6.
Malhi GS, Parker GB, Greenwood J: Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand 2005; 111: 94–105.
7.
Østergaard SD, Bille J, Søltoft-Jensen H, Lauge N, Bech P: The validity of the severity-psychosis hypothesis in depression. J Affect Disord 2012; 140: 48–56.
8.
Jääskeläinen E, Juola T, Korpela H, Lehtiniemi H, Nietola M, Korkeila J, et al: Epidemiology of psychotic depression – systematic review and meta-analysis. Psychol Med 2018; 48: 905–918.
9.
Caldieraro MA, Baeza FLC, Pinheiro DO, Ribeiro MR, Parker G, Fleck MP: Prevalence of psychotic symptoms in those with melancholic and nonmelancholic depression. J Nerv Ment Dis 2013; 201: 855–859.
10.
Schrijvers D, Hulstijn W, Sabbe BGC: Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool. J Affect Disord 2008; 109: 1–20.
11.
Buyukdura JS, McClintock SM, Croarkin PE: Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 395–409.
12.
Parker G: Defining melancholia: the primacy of psychomotor disturbance. Acta Psychiatr Scand 2007; 115(suppl 433): 21–30.
13.
Bennabi D, Vandel P, Papaxanthis C, Pozzo T, Haffen E: Psychomotor retardation in depression: a systematic review of diagnostic, pathophysiologic, and therapeutic implications. Biomed Res Int 2013; 2013: 158746.
14.
Sabbe B, Hulstijn W, Van Hoof J, Tuynman-Qua HG, Zitman F: Retardation in depression: assessment by means of simple motor tasks. J Affect Disord 1999; 55: 39–44.
15.
Sabbe B, Hulstijn W, Van Hoof J, Zitman F: Fine motor retardation and depression. J Psychiatr Res 1996; 30: 295–306.
16.
Pier MPBI, Hulstijn W, Sabbe BGC: Psychomotor retardation in elderly depressed patients. J Affect Disord 2004; 81: 73–77.
17.
Pier MPBI, Hulstijn W, Sabbe BGC: Differential patterns of psychomotor functioning in unmedicated melancholic and nonmelancholic depressed patients. J Psychiatr Res 2004; 38: 425–435.
18.
Beheydt LL, Schrijvers D, Docx L, Bouckaert F, Hulstijn W, Sabbe B: Psychomotor retardation in elderly untreated depressed patients. Front Psychiatry 2015; 5: 196.
19.
Tahmasian M, Khazaie H, Golshani S, Avis KT: Clinical application of actigraphy in psychotic disorders: a systematic review. Curr Psychiatry Rep 2013; 15: 359.
20.
Marino M, Li Y, Rueschman MN, Winkelman JW, Ellenbogen JM, Solet JM, et al: Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep 2013; 36: 1747–1755.
21.
van Londen L, Kerkhof GA, van den Berg F, Goekoop JG, Zwinderman KH, Frankhuij­zen-Sierevogel AC, et al: Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998; 43: 196–204.
22.
Volkers AC, Tulen JHM, Van Den Broek WW, Bruijn JA, Passchier J, Pepplinkhuizen L: Motor activity and autonomic cardiac functioning in major depressive disorder. J Affect Disord 2003; 76: 23–30.
23.
Sobin C, Sackeim HA: Psychomotor symptoms of depression. Am J Psychiatry 1997; 154: 4–17.
24.
Bracht T, Horn H, Strik W, Federspiel A, Schnell S, Höfle O, et al: White matter microstructure alterations of the medial forebrain bundle in melancholic depression. J Affect Disord 2014; 155: 186–193.
25.
Caligiuri MP, Ellwanger J: Motor and cognitive aspects of motor retardation in depression. J Affect Disord 2000; 57: 83–93.
26.
Iverson GL: Objective assessment of psychomotor retardation in primary care patients with depression. J Behav Med 2004; 27: 31–37.
27.
Parker G, Hadzi-Pavlovic D, Wilhelm K, Hickie I, Brodaty H, Boyce P, et al: Defining melancholia: properties of a refined sign-based measure. Br J Psychiatry 1994; 164: 316–326.
28.
Hasler G, Drevets WC, Manji HK, Charney DS: Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 1765–1781.
29.
Seidler RD, Bernard JA, Burutolu TB, Fling BW, Gordon MT, Gwin JT, et al: Motor control and aging: links to age-related brain structural, functional, and biochemical effects. Neurosci Biobehav Rev 2010; 34: 721–733.
30.
Taylor MA, Fink M: Melancholia. Cambridge, Cambridge University Press, 2006.
31.
Moffot A, O’Carroll RE, Bennie J, Carroll S, Dick H, Ebmeier KP, et al: Diurnal variation of mood and neuropsychological function in major depression with melancholia. J Affect Disord 1994; 32: 257–269.
32.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20): 22–33; quiz 34–57.
33.
Docx L, Sabbe B, Provinciael P, Merckx N, Morrens M: Quantitative psychomotor dysfunction in schizophrenia: a loss of drive, impaired movement execution or both? Neuropsychobiology 2013; 68: 221–227.
34.
Schrijvers D, Maas YJ, Pier MPBI, Madani Y, Hulstijn W, Sabbe BGC: Psychomotor changes in major depressive disorder during sertraline treatment. Neuropsychobiology 2009; 59: 34–42.
35.
Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, et al: A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 2009; 70: 177–184.
36.
Trajković G, Starčević V, Latas M, Leštarević M, Ille T, Bukumirić Z, et al: Reliability of the Hamilton Rating Scale for Depression: a meta-analysis over a period of 49 years. Psychiatry Res 2011; 189: 1–9.
37.
Østergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, et al: Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. J Affect Disord 2014; 160: 68–73.
38.
Østergaard SD, Pedersen CH, Uggerby P, Munk-Jørgensen P, Rothschild AJ, Larsen JI, et al: Clinical and psychometric validation of the Psychotic Depression Assessment Scale. J Affect Disord 2015; 173: 261–268.
39.
Rhebergen D, Arts DL, Comijs H, Beekman AT, Terwee CB, Parker G, et al: Psychometric properties of the Dutch version of the CORE measure of melancholia. J Affect Disord 2012; 142: 343–346.
40.
Attu SD, Rhebergen D, Comijs HC, Parker G, Stek ML: Psychomotor symptoms in depressed elderly patients: assessment of the construct validity of the Dutch CORE by accelerometry. J Affect Disord 2012; 137: 146–150.
41.
Middelkoop HAM, van Dam EM, Smilde-van den Doel DA, van Dijk G: 45-hour continuous quintuple-site actimetry: relations between trunk and limb movements and effects of circadian sleep-wake rhythmicity. Psychophysiology 1997; 34: 199–203.
42.
Parker G, Hadzi-Pavlovic D, Austin MP, Mitchell P, Wilhelm K, Hickie I, et al: Sub-typing depression, I. Is psychomotor disturbance necessary and sufficient to the definition of melancholia? Psychol Med 1995; 25: 815–823.
43.
Caldieraro MA, Vares EA, Spanemberg L, Radtke Becker F, Fleck MP: Association between CORE-assigned melancholia and the melancholia subscale of the HAM-D. J Affect Disord 2015; 172: 175–178.
44.
Spanemberg L, Caldieraro MA, Vares EA, Wollenhaupt-Aguiar B, Kauer-Sant’Anna M, Kawamoto SY, et al: Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure. Neuropsychiatr Dis Treat 2014; 10: 1523–1531.
45.
Walther S, Hügli S, Höfle O, Federspiel A, Horn H, Bracht T, et al: Frontal white matter integrity is related to psychomotor retardation in major depression. Neurobiol Dis 2012; 47: 13–19.
46.
Winkler D, Pjrek E, Lanzenberger R, Baldin­ger P, Eitel D, Kasper S, et al: Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy. J Psychiatr Res 2014; 57: 96–100.
47.
Razavi N, Horn H, Koschorke P, Hügli S, Höfle O, Müller T, et al: Measuring motor activity in major depression: the association between the Hamilton Depression Rating Scale and actigraphy. Psychiatry Res 2011; 190: 212–216.
48.
Krane-Gartiser K, Henriksen TEG, Vaaler AE, Fasmer OB, Morken G: Actigraphically assessed activity in unipolar depression: a comparison of inpatients with and without motor retardation. J Clin Psychiatry 2015; 76: 1181–1187.
49.
Adeosun II, Jeje O: Symptom profile and severity in a sample of Nigerians with psychotic versus nonpsychotic major depression. Depress Res Treat 2013; 2013: 815456.
50.
Gaudiano BA, Young D, Chelminski I, Zimmerman M: Depressive symptom profiles and severity patterns in outpatients with psychotic versus nonpsychotic major depression. Compr Psychiatry 2008; 49: 421–429.
51.
Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L: Phenomenology and prognostic significance of delusions in major depressive disorder: a 10-year prospective follow-up study. J Clin Psychiatry 2007; 68: 1411–1417.
52.
Thakur M, Hays J, Krishnan KR: Clinical, demographic and social characteristics of psychotic depression. Psychiatry Res 1999; 86: 99–106.
53.
Lattuada E, Serretti A, Cusin C, Gasperini M, Smeraldi E: Symptomatologic analysis of psychotic and non-psychotic depression. J Affect Disord 1999; 54: 183–187.
54.
Snowdon J: Should psychomotor disturbance be an essential criterion for a DSM-5 diagnosis of melancholia? BMC Psychiatry 2013; 13: 160.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.